Bluejay IPO Presentation Deck

Bluejay is Focused on Improving Patient Outcomes in Hospital/LTAC* Settings Using Symphony, a cost efficient, rapid, near-patient product candidate for triage, diagnosis and monitoring of disease progression Key Investment Highlights Advancing a novel & proprietary point of care diagnostic platform the Symphony System - for near term market availability Same proprietary instrument can be used for multiple clinical diagnostic tests and offers numerous competitive advantages Development path has been de-risked through 12+ years of development and 3+ years of clinical evaluation led by Toray Lead Symphony test is for IL-6 measurement for sepsis triage/monitoring Well established and diverse diagnostic market for all sepsis situations Existing IL-6 test options are reimbursed for a multi-billion dollar U.S. market A strong pipeline of new Symphony test applications in development will follow Strong near term value milestones targeted Experienced, successful leadership team well matched for commercial development of this product line bluejay TAC - Long Term Acute Care Toray Industries, Inc. Copyright 2021 Bluejay Diagnostics, Inc. All rights reserved in all slides | October 2021 20

View entire presentation